What the zemprocitinib enrollment milestone means for Lynk Pharmaceuticals’ late-stage pipeline
Lynk Pharmaceuticals completes Phase III zemprocitinib enrollment as ASAS40 efficacy, long-term safety and China filing tests move closer.
Pharma & Biotech